• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
SNT
Click for more information
0.00% 3.5¢

SYNTARA LIMITED - Charts / Financials

Market Cap $46.45M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

Syntara Limited is an Australia-based clinical-stage drug development company. The... Syntara Limited is an Australia-based clinical-stage drug development company. The Company is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.More

refresh Created with Sketch. REFRESH
Last update - 13.22pm 27/08/2024 (20 minute delay) ?
Day
Open 3.6¢   Day High 3.6¢   Day Low 3.4¢
Daily Volume 1220747
Bids   Sellers
Number Price Volume   Number Price Volume
1 3.4¢ 41808   3 3.5¢ 93952

Directors & Senior Management

Mr. Gary Jonathan Phillips Chief Executive Officer, Managing Director, Executive Director
Mr. David Morris Mcgarvey Chief Financial Officer, Company Secretary
Dr. Jana Baskar Chief Medical Officer
Mr. Wolfgang G. Jarolimek Head - Drug Discovery
Ms. Kristen Morgan Alliance Management and Head - Medical and Regulatory Affairs
Dr. Kathleen Mary Metters Non-Executive Chairman of the Board
Mr. Waradana Malitha Hashan De Silva Non-Executive Director
Dr. Simon P. Green Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last
3.5¢ 		Change
0.000(0.00%) 		Mkt cap ! $46.45M
Open High Low Value Volume
3.6¢ 3.6¢ 3.4¢ $43.08K 1.220M

Buyers (Bids)

No. Vol. Price($)
1 41808 3.4¢
 

Sellers (Offers)

Price($) Vol. No.
3.5¢ 93952 3
View Market Depth
Last trade - 13.05pm 27/08/2024 (20 minute delay) ?
Last
3.5¢ 		  Change
0.000 ( 1.45 %)
Open High Low Volume
3.5¢ 3.6¢ 3.4¢ 663643
Last updated 13.22pm 27/08/2024 ?

Top Stories

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

A southward cluster of outcropping pegmatites on-site Chariot Corporation's (ASX:CC9) flagship Black Mountain hard rock lithium project has led management and geotechs to sign off on a promising future drilling target for the company as exploration on-site gathers pace.
Week 34 Wrap: HotCopper's top watched; Oz banks cut saver interest; Kamala’s 28% corporate tax; AI’s back This week’s biggest story (in my view) for the Australian economy actually started late last week. Quietly, CBA cut its term deposit interest rates, prompting ANZ and NAB to do the same on Monday of this week.
The Rising Tide: How institutional adoption is shaping the future of crypto This year's institutional demand for Bitcoin supports stability & credibility for the asset class. We look at what's happened since crypto ETFs were approved in the US & what that means for Australian investors.
How flooding did Strategic Energy Resources a favour: Four holes down in 'redesigned' gold & copper campaign Strategic Energy Resources is 4 holes into a 40-hole RC drill campaign at its Achilles 1 copper-gold target in the Cobar Basin of NSW.
Why are so many ASX explorers setting up shop in Saudi Arabia? + 8 stocks to watch You may have noticed in the last few years the name of a particular Kingdom popping up quite a lot on the ASX.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.